Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BOS-475 in Healthy Subjects and Psoriasis Patients
NCT03960450Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3183475 in plaque psoriasis (4 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Number of participants with any adverse event (AEs) and any serious adverse event (SAE), Change from baseline in the application site tolerability assessment score and 3 more. Started Apr 2019; status: completed.
02
Drugs
GSK3183475
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03960450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960450.